加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$44.02
−US$1.21 · -2.68%
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
收盘时
US$44.02
−US$1.21 · -2.68%
盘后
US$43.80
−US$0.22 · -0.50%
10月12日 19:49 ET
盘中时间采用ET。市场数据可能有所延迟。
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
日内区间
当前US$44.02
52周区间
当前US$44.02
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
37
偏贵
情绪
60
多空交织
风险
47
风险偏高
动量
69
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
日内区间
当前US$44.02
52周区间
当前US$44.02
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.17亿 USD | 4.46亿 USD | 3.61亿 USD | 2.97亿 USD | 2.2亿 USD |
| 销货成本 | 1.57亿 USD | 1.48亿 USD | 1.13亿 USD | 1.02亿 USD | 7440万 USD |
| 毛利 | 3.6亿 USD | 2.98亿 USD | 2.48亿 USD | 1.95亿 USD | 1.45亿 USD |
| 研究与开发 | 7081.4万 USD | 6929.4万 USD | 5730.5万 USD | 4060.3万 USD | 2984.3万 USD |
| 销售、一般及管理费用 | 2.11亿 USD | 2.06亿 USD | 1.84亿 USD | 1.74亿 USD | 1.81亿 USD |
| 营业费用 | 2.86亿 USD | 2.82亿 USD | 3.34亿 USD | 2.36亿 USD | 2.27亿 USD |
| 利息收入 | — | 1115.4万 USD | 734.4万 USD | 197.2万 USD | 13.5万 USD |
| 利息支出 | — | 2000 USD | 1.5万 USD | 19.8万 USD | 24.1万 USD |
| 折旧和摊销 | 2141.5万 USD | 2345.9万 USD | 2718.8万 USD | 2592.8万 USD | 1959.3万 USD |
| 营业利润 | 7415万 USD | 1614.2万 USD | −8579.5万 USD | −4108.1万 USD | −8190.3万 USD |
| 净利润 | 6635.3万 USD | 2413.8万 USD | −7440.4万 USD | −3656万 USD | −7556.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.1亿0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1.04亿1.05%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM9546.64万0.12%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB7924.64万0.04%1853亿 USD0.03%US$288.16-0.46%
First Trust NYSE Arca Biotechnology Index FundFBT7187.92万2.49%28.91亿 USD0.55%US$263.9-0.57%
ARK Genomic Revolution ETFARKG7027.3万3.30%15.57亿 USD0.75%US$49.48-3.55%
ARK Innovation ETFARKK6683.61万1.00%55.62亿 USD0.75%US$88.02-1.79%
Vanguard Morningstar Small-Cap Growth ETFVBK4561.23万0.10%447亿 USD0.05%US$340.88-1.12%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBFirst Trust NYSE Arca Biotechnology Index FundFBTARK Genomic Revolution ETFARKGARK Innovation ETFARKKVanguard Morningstar Small-Cap Growth ETFVBKAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
